OakChart

BeyondSpring Inc

BYSIHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 3:59 PM ET

0.6438+0.0641 (11.06%)
2026-11-12 01:41 CET
Market cap
23.84 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-6.69 USD m
Free cash flow, TTM
-17.05 USD m
EPS diluted, TTM
-0.16
P/E
-
Compare

Price

BYSI against its 20, 50 and 200-day averages
2050200earnings
0.501.001.502.0019.5M39.0MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26BYSIclose 0.6420-day 0.5750-day 0.66200-day 1.230.6452w low

73.6% under the 52-week high of 2.44 on 12 Dec 2025. 52-week low 0.42 on 22 Oct 2026. Last 15 sessions, 113.1% high to low

Volume 0.09× normal · the line is the 50-bar volume average

Profile

BYSI
52-week range, 11% of the way up
0.422.44

BeyondSpring, Inc. engages in the development and commercialization of immuno-oncology cancer therapies. It operates through the Plinabulin Pipeline and TPD Platform segments. The Plinabulin Pipeline segment focuses on the development of cancer therapies. The TPD Platform segment engages in the development of therapeutic agents and discover chemical entities. The company was founded by Lan Huang and Lin Qing Jia in 2010 and is headquartered in Florham Park, NJ.

Employees44
IPOMar 09, 2017
Beta-0.12
ATR, 14d0.11
Rel volume0.09
Short float7.13%
Insider own22.31%
Inst own5.49%

Snapshot

6 groups

Valuation

Index-
Market Cap26.48M
Enterprise Value19.66M
Income-6.69M
Sales0.00M
Book/sh-0.86
Cash/sh0.16
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees44
IPOMar 09, 2017

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B-
P/C4.05
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio0.70
Current Ratio0.70
Debt/Eq-
LT Debt/Eq-
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.16
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y38.52% 37.25%
Sales past 3/5Y- -
EPS Y/Y TTM58.89%
Sales Y/Y TTM-
EPS Q/Q54.02%
Sales Q/Q-
Earnings-
EPS/Sales Surpr.- -

Ownership

Insider Own22.31%
Insider Trans0.00%
Inst Own5.49%
Inst Trans0.57%
ROA-31.92%
ROE-
ROIC-
Gross Margin-
Oper. Margin-
Profit Margin-
SMA2013.34%
SMA50-1.83%
SMA200-47.75%
Trades-

Technical

Shs Outstand41.12M
Shs Float31.95M
Short Float7.13%
Short Ratio2.60
Short Interest2.28M
52W High2.44 -73.61%
52W Low0.42 52.74%
Volatility18.47% 18.73%
ATR (14)0.11
RSI (14)51.89
Beta-0.12
Rel Volume0.09
Avg Volume875.68K
Volume78,307

Performance

Perf Week-5.18%
Perf Month6.12%
Perf Quarter-35.38%
Perf Half Y-55.60%
Perf YTD-60.50%
Perf Year-70.74%
Perf 3Y-31.51%
Perf 5Y-95.69%
Perf 10Y-
Recom2.00
Target Price1.25
Prev Close0.58
Price0.64
Change %11.06%

Analyst ratings

latest 10 of 15
DateActionAnalystRating changeTargetImplied
Dec 02, 2021DowngradeJJefferiesBuy → Hold$38 → $5+676.6%
Dec 02, 2021DowngradeBBofA SecuritiesBuy → Underperform$45 → $5+676.6%
Dec 01, 2021DowngradeWWilliam BlairOutperform → Mkt Perform
Dec 01, 2021DowngradeHH.C. WainwrightBuy → Neutral
Sep 09, 2021InitiatedRRobert W. BairdOutperform$50+7,666.4%
Aug 04, 2021UpgradeHH.C. WainwrightNeutral → Buy$100+15,432.8%
Apr 05, 2021DowngradeHH.C. WainwrightBuy → Neutral
Jan 11, 2021InitiatedBBofA SecuritiesBuy$25+3,783.2%
Dec 29, 2020InitiatedEEvercore ISIOutperform$30+4,559.8%
Feb 07, 2020InitiatedJJefferiesBuy$25+3,783.2%

Peers

Mkt cap
TickerCompanyMkt cap
IMMPImmutep Limited ADR26.24M
LTRNLantern Pharma Inc7.19M
GLUEMonte Rosa Therapeutics Inc880.99M
BDTXBlack Diamond Therapeutics Inc92.50M
CCCCC4 Therapeutics Inc379.51M
GNPXGenprex Inc1.87M
ARVNArvinas Inc452.51M
KYMRKymera Therapeutics Inc11.51B
NRIXNurix Therapeutics Inc1.78B
IOVAIovance Biotherapeutics Inc3.74B

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWCiShares Micro-Cap ETFAUM: 1.22B

News

latest 14 of 200
  • BeyondSpring Secures FDA Fast Track Designation for Plinabulin as DUBLIN-4 Phase 3 Trial Advances (InvestorsHub) -30.96%
  • BeyondSpring Announces FDA Fast Track Designation for Plinabulin in Post-ICI Non-Squamous NSCLC and Strategic Transaction to Advance Global Phase 3 DUBLIN-4 Trial Toward Planned Interim Analysis (GlobeNewswire)
  • BeyondSpring Reports Second-Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire) -15.78% -15.21%
  • BeyondSpring Announces Leadership Transition to Deliver Focused Execution on Its Confirmatory DUBLIN-4 Program and Long-Term Value (GlobeNewswire)
  • BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026 (GlobeNewswire)
  • BeyondSpring Announces Poster Presentation at 2026 ASCO Annual Meeting (GlobeNewswire)
  • BeyondSpring shares rise after narrower quarterly loss and pipeline advances (BYSI) (InvestorsHub)
  • BeyondSpring Reports First-Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
  • BeyondSpring Reports Compelling New Data: Plinabulin Advances Both the Anticancer Efficacy and Safety of ADC Drugs (GlobeNewswire) -6.32%
  • BeyondSpring Announces Plinabulin and ADC Combination Poster Presentation at AACR Annual Meeting 2026 (GlobeNewswire)
  • BeyondSpring Files 2025 Annual Report on Form 10-K (GlobeNewswire)
  • BeyondSpring Reports 2025 Year-End Financial Results (GlobeNewswire)
  • BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360 Conference (GlobeNewswire)
  • BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q12026-05-13---0.050---
2025Q32025-11-12---0.040---
2025Q22025-08-13---0.040---
2025Q12025-05-120.110-0.1100.34--
2021Q32022-12-29-0.470-0.583-0.4710.340.173
2022Q32022-12-22-0.440--0.4400.34--
2022Q12022-06-16-0.230-0.230-0.2300.340.341
2021Q42022-04-14-0.240-0.290-0.2400.330.275
2021Q22021-09-10-0.490-0.485-0.4950.348.774
2021Q12021-06-16-0.440-0.540-0.4360.340.004
2020Q42021-04-30-0.520-0.448-0.5200.180.00-
2020Q32020-11-17-0.480-0.540-0.4800.000.00-
2020Q22020-09-03-0.460-0.570-0.4570.000.004
2020Q12020-06-11-0.580-0.465-0.5800.000.00-
2019Q42020-04-30-0.520-0.432-0.5190.000.005
2019Q32019-12-18-0.370-0.395-0.3700.000.002

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2016FY-0.750-0.560-0.5500.000.00
2017FY-4.400-4.448-4.4000.000.00
2018FY-2.420--2.4210.00-
2019FY-1.550-1.528-1.5450.000.00
2020FY-2.030-1.850-2.0340.180.00
2021FY-1.640-1.550-1.6451.351.27
2022FY-0.850-0.880-0.8511.3531.01
2023FY-0.540--0.5391.75-
2024FY-0.280--0.2801.75-

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2023FYS2023-07-151001.351.351.35
2023FYS2023-07-061011.351.351.35
2023FYR2023-07-15100-0.47-0.47-0.47
2023FYR2023-07-06110-0.47-0.47-0.47
2023FYE2023-07-15100-0.47-0.47-0.47
2023FYE2023-07-06110-0.47-0.47-0.47

Estimate history

EPS, annual-4.4-2.421-1.545-2.034-1.645-0.851-0.539-0.28-0.198-0.1639
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.436-0.495-0.471-0.062-0.045-0.038-0.053-0.053-0.021
PeriodQ1 '21Q2 '21Q3 '21Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0000.181.3511.3510000
Period201720182019202020212022202320242025TTM
Sales, quarterly0.3380.3380.337000000
PeriodQ1 '21Q2 '21Q3 '21Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual22.53123.18527.88639.14238.9283939.02940.31641.12241.12
Period201720182019202020212022202320242025MRQ
Shares, quarterly39.10639.11539.14240.31640.32240.32241.12241.1241.12
PeriodQ1 '21Q2 '21Q3 '21Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.001.351.350.180.000.00
Cost of Goods Sold Incl. D&A0.080.090.290.30--0.080.080.05
Gross Profit-0.08-0.09-0.28-0.30--0.10-0.08-0.05
Selling, General and Administrative Excl. Other8.278.868.4714.7837.4567.5364.3140.2357.50
Research and Development4.564.392.647.2725.5836.8941.7931.3451.62
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-8.35-8.95-8.75-15.08-37.24-66.24-64.21-40.31-57.55
Interest Expense--0.000.000.020.090.090.210.00
Unusual Expense0.000.000.000.000.000.000.00--
Net Income Before Taxes-8.01-8.63-8.77-13.92-36.12-64.64-63.82-40.33-57.47
Income Taxes0.340.090.100.090.163.570.000.000.00
Consolidated Net Income-8.35-8.72-8.87-14.02-36.28-68.21-63.82-40.33-57.47
Net Income From Continuing Operations-7.29-8.47-8.48-13.09-33.28-64.18-60.97-38.09-54.87
Net Income-6.69-7.99-11.12-21.03-33.28-64.18-60.97-38.09-54.87
EPS (Recurring)-0.16-0.20-0.28-0.54-0.85-1.64-2.03-1.55-2.42
EPS (Basic, Before Extraordinaries)-0.16-0.20-0.28-0.54-0.85-1.64-2.03-1.55-2.42
EPS (Diluted)-0.16-0.20-0.28-0.54-0.85-1.64-2.03-1.55-2.42
EBITDA-8.27-8.86-8.47-14.78-36.09-66.18-64.13-40.23-57.50
Non-Operating Income (Expense)0.340.32-0.011.161.141.690.480.180.07
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.640.391.630.441.252.366.151.584.92
Price To Sales Ratio---20.0454.40130.852,032.27--
Gross Margin------57.22--
Operating Margin-----2,756.40-4,903.03-35,672.78--
Net Margin-----2,463.29-4,750.48-33,873.89--
Shares Outstanding41.1241.1240.3239.0339.0038.9339.1427.8923.18
Market Capitalization23.8423.8465.6935.0373.19177.19477.53431.15434.53

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12021Q3
Total Revenue0.000.000.000.000.000.00-0.34
Cost of Goods Sold Incl. D&A0.020.020.020.020.080.08--
Gross Profit-0.02-0.02-0.02-0.02-0.08-0.08--
Selling, General and Administrative Excl. Other1.712.212.571.771.872.53-18.67
Research and Development0.971.081.471.041.000.87-8.46
Other Operating Expense0.000.000.000.000.000.00-0.00
Operating Income-1.73-2.23-2.60-1.79-1.95-2.61--18.35
Interest Expense0.00---0.000.00-0.02
Unusual Expense0.000.000.000.000.000.00-0.00
Net Income Before Taxes-1.65-2.16-2.49-1.72-1.86-2.56--17.56
Income Taxes0.100.190.020.030.020.02-2.59
Consolidated Net Income-1.75-2.35-2.51-1.74-1.88-2.58--20.14
Net Income From Continuing Operations-0.91-2.22-2.37-1.78-1.81-2.51--18.37
Net Income-0.85-2.16-2.14-1.54-1.81-2.51--18.37
EPS (Recurring)-0.02-0.05-0.05-0.04-0.04-0.06--0.47
EPS (Basic, Before Extraordinaries)-0.02-0.05-0.05-0.04-0.04-0.06--0.47
EPS (Diluted)-0.02-0.05-0.05-0.04-0.04-0.06--0.47
EBITDA-1.71-2.21-2.57-1.77-1.87-2.53--18.33
Non-Operating Income (Expense)0.080.070.110.070.090.05-0.81
Other After Tax Adjustments0.000.000.000.000.000.00-0.00
Stock Option Compensation Expense0.450.060.050.070.140.17-1.31
Price To Sales Ratio-------515.53
Operating Margin--------5,444.81
Net Margin--------5,451.04
Shares Outstanding41.1241.1241.1240.3240.3240.32-39.14
Market Capitalization23.8467.4467.0373.0094.7457.83-616.46

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments12.562.9215.3437.2772.37109.5435.933.8930.55
Short Term Receivables0.000.000.000.000.000.000.000.000.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets8.3225.663.081.252.753.864.931.981.79
Total Current Assets20.8828.5818.4238.5275.12113.4040.865.8732.34
Net Property, Plant & Equipment0.470.751.057.353.412.362.750.280.12
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets--------0.00
Other Assets4.584.995.340.353.121.280.950.910.36
Total Assets25.9334.3124.8146.2281.65117.0444.557.0632.83
Short Term Debt Incl. Current Port. of LT Debt0.320.280.260.972.110.790.570.000.00
Accounts Payable0.360.290.561.081.662.222.549.593.38
Income Tax Payable0.250.000.020.02-----
Other Current Liabilities12.6410.437.125.2911.3910.766.956.861.41
Total Current Liabilities13.5811.017.967.3515.1513.7710.0516.454.79
Long Term Debt0.000.310.594.001.473.533.370.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.00-
Other Liabilities36.3537.2839.7237.8838.657.920.000.000.00
Total Liabilities49.9248.6048.2749.2355.2725.2213.4216.454.79
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity-32.16-32.90-26.80-5.9826.6888.3430.28-7.7727.08
Total Shareholders Equity-32.16-32.90-26.80-5.9826.6888.3430.28-7.7727.08
Accumulated Minority Interest8.1718.613.342.97-0.313.480.85-1.620.96
Total Equity-23.99-14.29-23.46-3.0126.3891.8231.13-9.3828.04
Total Liabilities & Stockholders Equity25.9334.3124.8146.2281.65117.0444.557.0632.83
Book Value Per Share-0.78-0.82-0.69-0.150.692.261.09-0.331.20
Tangible Book Value Per Share-0.78-0.82-0.69-0.150.692.261.09-0.331.20
Full-Time Employees444035737691615238
Price to Book Ratio-0.67-2.18-1.942.746.615.4114.28-55.9816.97
Return on Assets-28.13-28.68-36.87-52.05-64.60-75.46-147.56-275.09-384.46
Return on Equity----321.46-111.59-102.81-338.37-568.30-467.84
Return on Invested Capital-----227.97-66.37-113.19--338.91
Quick Ratio1.542.602.315.244.968.244.060.366.75
Current Ratio1.542.602.315.244.968.244.060.366.75

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-23.40-14.22-16.69-21.95-36.28-68.21-63.82-40.33-57.47
Depreciation-0.040.090.290.301.140.060.080.080.05
Other Funds (Non Cash)2.09-5.522.951.891.261.958.192.106.25
Funds from Operations-21.35-19.65-13.45-19.76-33.87-66.20-55.55-38.16-51.17
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital4.30-0.38-2.930.63-3.7631.9811.81-10.0111.22
Cash from Operating Activities-17.05-20.02-16.38-19.13-37.64-34.22-43.75-48.16-39.96
Capital Expenditures-0.00-0.05-0.22-0.10-0.03-2.84-0.05-0.00-0.21
Net Assets From Acquisitions-0.03-0.03-0.100.000.00-0.040.000.000.00
Sale of Fixed Assets and Businesses3.1210.0720.000.005.720.005.3110.08-
Purchase or Sale of Investments-1.843.48-11.790.0017.56-17.570.000.003.07
Purchase of Investments-32.49-14.95-12.79-1.30-32.20-44.230.000.000.00
Sale Or Maturity of Investments30.6518.431.001.3049.7626.660.000.003.07
Other Uses0.000.000.000.00-0.690.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities1.2613.487.89-0.1022.56-20.455.2610.082.87
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock2.011.992.970.000.000.04111.6468.5713.25
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock2.011.992.970.000.000.04111.6468.5713.25
Proceedsfrom Stock Options2.011.992.970.000.000.04111.6468.5713.25
Issuance or Reduction of Debt, Net0.000.293.910.00-1.570.000.611.520.00
Change in Long Term Debt0.000.000.000.000.000.000.641.490.00
Issuance of Long Term Debt0.000.000.000.000.000.000.642.990.00
Reduction of Long Term Debt0.000.000.000.000.000.000.00-1.490.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.280.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities-2.242.276.880.00-1.570.04112.5270.0913.25
Exchange Rate Effect0.140.11-0.03-0.08-0.76-0.26-0.430.040.25
Net Change in Cash-17.90-4.16-1.64-19.30-17.40-54.8973.6032.04-23.59
Free Cash Flow-17.05-20.07-16.60-19.23-37.67-37.06-43.80-48.17-40.16
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments6.537.8612.5612.629.548.53
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets3.375.648.3211.7916.1723.00
Total Current Assets9.9013.5020.8824.4125.7131.53
Net Property, Plant & Equipment0.310.390.470.550.630.71
Total Investments and Advances0.000.000.000.000.000.00
Other Assets4.394.514.584.524.704.87
Total Assets14.6118.4125.9329.4831.0437.10
Short Term Debt Incl. Current Port. of LT Debt0.170.250.320.310.310.30
Accounts Payable0.790.650.360.300.270.36
Income Tax Payable--0.250.000.000.00
Other Current Liabilities13.2311.4812.6412.2711.1612.01
Total Current Liabilities14.1912.3713.5812.8911.7312.66
Long Term Debt0.000.000.000.090.170.25
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities36.4436.3936.3536.3136.6936.86
Total Liabilities50.6348.7649.9249.2948.5949.77
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity-35.57-34.49-32.16-31.77-30.22-28.31
Total Shareholders Equity-35.57-34.49-32.16-31.77-30.22-28.31
Accumulated Minority Interest-0.464.138.1711.9612.6715.64
Total Equity-36.02-30.35-23.99-19.81-17.55-12.67
Total Liabilities & Stockholders Equity14.6118.4125.9329.4831.0437.10
Book Value Per Share-0.86-0.84-0.78-0.79-0.75-0.70
Tangible Book Value Per Share-0.86-0.84-0.78-0.79-0.75-0.70
Full-Time Employees--44---
Price to Book Ratio-0.67-2.10-2.07-2.42-3.35-1.92
Return on Assets-31.92-29.48----
Quick Ratio0.701.091.541.892.192.49
Current Ratio0.701.091.541.892.192.49

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-5.80-6.67-5.92-5.01-4.661.17
Depreciation0.020.020.02-0.100.080.08
Other Funds (Non Cash)0.780.650.150.500.31-6.56
Funds from Operations-5.00-6.00-5.74-4.61-4.27-5.31
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital1.172.730.090.31-1.640.86
Cash from Operating Activities-3.83-3.28-5.65-4.29-5.90-4.45
Capital Expenditures0.000.00-0.00-0.00-0.00-0.05
Net Assets From Acquisitions0.000.00-0.030.000.000.00
Sale of Fixed Assets and Businesses0.000.280.052.797.380.00
Purchase or Sale of Investments0.034.48-5.18-1.173.536.35
Purchase of Investments-15.19-7.16-7.85-2.29-2.01-3.00
Sale Or Maturity of Investments15.2211.642.671.125.549.35
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.034.76-5.151.6210.906.30
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock-0.00-0.012.02-0.000.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock-0.00-0.012.02-0.000.000.00
Proceedsfrom Stock Options-0.00-0.012.02-0.000.000.00
Issuance or Reduction of Debt, Net-0.11-4.430.010.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities-0.11-4.442.030.280.000.00
Exchange Rate Effect0.010.020.12-0.01-0.010.00
Net Change in Cash-3.90-2.93-8.66-2.404.991.86
Free Cash Flow-3.83-3.28-5.65-4.29-5.90-4.50

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-307.13%2.3M32.0M850.03K
2026-10-157.37%2.4M32.0M844.32K
2026-09-307.65%2.4M32.0M851.44K
2026-09-157.15%2.3M32.0M692.50K
2026-08-317.22%2.3M32.0M665.28K
2026-08-148.54%2.7M32.0M660.88K
2026-07-317.20%2.2M31.2M24.37K
2026-07-157.14%2.2M31.2M22.15K
2026-06-307.11%2.2M31.2M17.90K
2026-06-157.07%2.2M31.2M18.38K
2026-05-297.09%2.2M31.2M20.04K
2026-05-157.00%2.2M31.2M17.33K
2026-04-307.02%2.2M31.2M19.21K
2026-04-157.03%2.2M31.2M22.49K
2026-03-317.04%2.2M31.2M29.46K
2026-03-137.01%2.2M31.2M59.77K
2026-02-277.15%2.2M31.2M257.64K
2026-02-137.16%2.2M31.2M258.67K
2026-01-307.44%2.3M31.0M258.04K
2026-01-157.74%2.4M31.0M260.89K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.000.050.046.5641350.000.205-0.0110.000
call5.000.000.500.008.4160.000.000.180-0.0120.000
call7.500.000.500.009.3960.000.000.171-0.0130.000
put2.501.702.200.0014.4590.000.00-0.795-0.0100.000
put5.004.004.800.0019.6360.000.00-0.820-0.0120.000
put7.506.407.400.0025.3230.000.00-0.829-0.0130.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-29SCHEDULE 13G/ASEC
2026-10-138-KCurrent report2026-10-13SEC
2026-10-068-KCurrent report2026-09-30SEC
2026-10-028-KCurrent report2026-09-29SEC
2026-09-298-KCurrent report2026-09-29SEC
2026-09-29424B5SEC
2026-09-188-KCurrent report2026-09-17SEC
2026-09-03DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-09-03DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-10-13SEC
2026-09-03ARSAnnual report to security holders. 2025-12-31SEC
2026-08-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-148-KCurrent report2026-08-14SEC
2026-08-14SCHEDULE 13G/ASEC
2026-07-064Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-064Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-063Initial statement of beneficial ownership of securities2026-07-01SEC
2026-07-063Initial statement of beneficial ownership of securities2026-07-01SEC
2026-06-298-K/A2026-06-04SEC
2026-06-048-KCurrent report2026-06-04SEC
2026-05-154Statement of changes in beneficial ownership of securities2026-03-20SEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-138-KCurrent report2026-05-13SEC
2026-04-084Statement of changes in beneficial ownership of securities2026-04-01SEC
2026-04-034Statement of changes in beneficial ownership of securities2026-04-01SEC
2026-04-034Statement of changes in beneficial ownership of securities2026-04-01SEC
2026-04-034Statement of changes in beneficial ownership of securities2026-04-01SEC
2026-04-034Statement of changes in beneficial ownership of securities2026-04-01SEC
2026-04-034Statement of changes in beneficial ownership of securities2026-04-01SEC
2026-04-034Statement of changes in beneficial ownership of securities2026-04-01SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Decheng Capital LLC9.24%
BlackRock, Inc.1.64%
VANGUARD CAPITAL MANAGEMENT LLC1.52%
GEODE CAPITAL MANAGEMENT, LLC0.89%
STATE STREET CORP0.56%
VANGUARD FIDUCIARY TRUST CO0.44%
NORTHERN TRUST CORP0.15%
UBS Group AG0.13%
Farther Finance Advisors, LLC0.03%
RENAISSANCE TECHNOLOGIES LLC0.03%

Funds

Fund% owned
VANGUARD EXTENDED MARKET INDEX FUND0.83%
VANGUARD TOTAL STOCK MARKET INDEX FUND0.69%
Fidelity Extended Market Index Fund0.38%
iShares Micro-Cap ETF0.26%
Fidelity Total Market Index Fund0.16%
Fidelity Series Total Market Index Fund0.10%
Fidelity Nasdaq Composite Index Fund0.05%
1290 VT Micro Cap Portfolio0.02%
Guggenheim Active Allocation Fund0.00%

OakChart. BYSI. Cached 15 minutes.

Some panels did not load: insider.